新型化合物作为LPAR1抑制剂用于治疗系统性硬化症
1Arclin USA LLC, 1150 Sanctuary Parkway, Suite 100, Alpharetta, Georgia 30009, United States.
ACS medicinal chemistry letters
|February 18, 2026
概括
介绍了抑制 lysophosphatidic 酸受体 1 (LPAR1) 的新化合物. 这些LPAR1抑制剂显示出治疗系统性硬化症的潜力.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 系统性硬化症是一种复杂的自身免疫性疾病,以纤维化为特征.
- lysophosphatidic 酸受体 1 (LPAR1) 在纤维化过程中发挥作用.
研究的目的:
- 引入针对LPAR1.1的新型化合物.
- 探索这些化合物在治疗系统性硬化症中的治疗潜力.
主要方法:
- 新型化学实体的合成.
- 对LPAR1抑制的药理学评估.
- 在全身性硬化症的临床前模型中评估疗效.
主要成果:
- 新型LPAR1抑制剂已成功合成.
- 这些化合物表现出强烈的LPAR1.1抑制.
- 这些化合物在改善全身性硬化症表型方面表现有前途.
结论:
- 开发的化合物代表了一类新的LPAR1抑制剂.
- 这些抑制剂在全身性硬化症治疗中具有治疗前景.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
1.9K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
529
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
529
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
492
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
492
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
633
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
633
Pharmacogenomics: Identification of New Drug Targets
20
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
20


